IGC Pharma Inc. announced that it has reached approximately 70% of planned patient enrollment in its Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease. The study is being conducted across approximately 23 active sites in 26 locations, with enrollment expected to be completed by mid-2026. IGC-AD1 is an investigational, cannabinoid-based therapy assessed in a randomized, double-blind, placebo-controlled trial aimed at evaluating its safety and efficacy. The company has not yet presented results from this trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IGC Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1132238) on February 02, 2026, and is solely responsible for the information contained therein.